Cargando…

The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01(E) and MVA85A

Background: Tuberculosis (TB) is a severe infectious disease with devastating effects on global public health. No TB vaccine has yet been approved for use on latent TB infections and healthy adults. In this study, we performed a systematic review and meta-analysis to evaluate the immunogenicity and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ullah, Inayat, Bibi, Shaheen, Ul Haq, Ijaz, Safia, Ullah, Kifayat, Ge, Long, Shi, Xintong, Bin, Ma, Niu, Hongxia, Tian, Jinhui, Zhu, Bingdong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578575/ https://www.ncbi.nlm.nih.gov/pubmed/33133057 http://dx.doi.org/10.3389/fimmu.2020.01806

Ejemplares similares

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2008)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2011)

Synthesis, structural characterization and catalytic application of citrate-stabilized monometallic and bimetallic palladium@copper nanoparticles in microbial anti-activities
por: Ullah, Inayat, et al.
Publicado: (2017)

In silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology
por: Bibi, Shaheen, et al.
Publicado: (2021)

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A
por: Tanner, Rachel, et al.
Publicado: (2014)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

PMM 85.01
Publicado: (1985)

CCM 85-01
Publicado: (1985)

MVA85A vaccine to enhance BCG for preventing tuberculosis
por: Kashangura, Rufaro, et al.
Publicado: (2019)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, Angela M, et al.
Publicado: (2011)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
por: Morelli, María Paula, et al.
Publicado: (2020)

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
por: Betts, Gareth, et al.
Publicado: (2012)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: Kashangura, Rufaro, et al.
Publicado: (2015)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: McShane, Helen, et al.
Publicado: (2016)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
por: Riste, Michael, et al.
Publicado: (2021)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
por: Wilkie, Morven, et al.
Publicado: (2020)

Safety and immunogenicity of candidate vaccine M72/AS01(E) in adolescents in a TB endemic setting
por: Penn-Nicholson, Adam, et al.
Publicado: (2015)

Immunogenicity and Safety of the M72/AS01(E) Candidate Vaccine Against Tuberculosis: A Meta-Analysis
por: Ji, Zhenhua, et al.
Publicado: (2019)

Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
por: Dieye, Tandakha N., et al.
Publicado: (2013)

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
por: Tameris, Michele, et al.
Publicado: (2014)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
por: Ndiaye, Birahim Pierre, et al.
Publicado: (2015)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
por: Dieye, Tandakha N., et al.
Publicado: (2013)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Inhibition of SARS-CoV-2 3CL M(pro) by Natural and Synthetic Inhibitors: Potential Implication for Vaccine Production Against COVID-19
por: Ullah, Anwar, et al.
Publicado: (2021)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
por: Nadeem, Aroosa Younis, et al.
Publicado: (2022)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination
por: Bunyasi, E. W., et al.
Publicado: (2017)

Violence Detection Using Spatiotemporal Features with 3D Convolutional Neural Network
por: Ullah, Fath U Min, et al.
Publicado: (2019)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
por: Satti, Iman, et al.
Publicado: (2014)

A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults
por: Kumarasamy, Nagalingeswaran, et al.
Publicado: (2016)

Systematic Analysis of Poly(o-aminophenol) Humidity Sensors
por: Bibi, Salma, et al.
Publicado: (2017)

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_plo93vloes2jkm3qs25h1v7ur4